6-Thioguanine Inhibits EV71 Replication by Targeting BIRC3-Mediated Autophagy

Study Background and Research Question

Enterovirus 71 (EV71) is a positive-sense, single-stranded RNA virus recognized as a primary causative agent of hand, foot, and mouth disease (HFMD), predominantly affecting children under five. While most HFMD cases are self-limiting, EV71 infections can escalate to severe neurological complications and even fatality. Although inactivated vaccines achieve high efficacy against certain EV71 strains, genotype diversity and limited cross-protection leave significant gaps in clinical management. Currently, no targeted antiviral therapies for EV71 are available, prompting the search for agents with novel mechanisms of action. In this context, You et al. investigated the antiviral properties of 6-thioguanine (6-TG), an FDA-approved thiopurine drug, focusing on its effects on EV71 replication and the underlying cellular pathways in human intestinal epithelial cells (You et al., 2025).

Key Innovation from the Reference Study

The core innovation of the study lies in the identification of 6-TG as a potent inhibitor of EV71 replication through a specific modulation of host cell autophagy machinery. The authors demonstrate that 6-TG exerts its antiviral effect by downregulating baculoviral IAP repeat containing 3 (BIRC3), a cellular protein implicated in autophagic processes. This mechanistic insight bridges prior knowledge of 6-TG's anti-cancer and anti-inflammatory activity with a novel antiviral application, distinguishing it from standard approaches that target viral proteins directly.

Methods and Experimental Design Insights

The study utilized the human colon adenocarcinoma cell line HT-29 as an in vitro model for EV71 infection. Key methodological highlights include:

• Assessment of 6-TG cytotoxicity and antiviral potency, with CC₅₀ and IC₅₀ calculations.
• Quantification of viral replication by measuring EV71 mRNA, VP1 protein expression, and infectious progeny production following 6-TG treatment.
• Western blot and qPCR analyses to evaluate the expression of BIRC3 and key autophagy markers.
• Functional assays to dissect autophagic flux in response to 6-TG and EV71 infection.

This systematic design enabled the authors to dissect both the antiviral efficacy and the host cellular targets affected by 6-TG.

Core Findings and Why They Matter

The principal findings are as follows:

• Potent antiviral activity: 6-TG reduced EV71 mRNA, VP1 protein levels, and viral progeny in HT-29 cells. The IC₅₀ for EV71 inhibition was 0.93 μM, while the CC₅₀ exceeded 2000 μM, yielding a selectivity index (SI) > 2150—substantially higher than that of ribavirin, a reference antiviral (You et al., 2025).
• Autophagy modulation: 6-TG treatment attenuated the complete autophagic response induced by EV71, as evidenced by decreased BIRC3 expression and downstream autophagy markers.
• Mechanistic specificity: The study clarifies that the antiviral effect is mediated via host cell autophagy regulation rather than direct interference with viral RNA or protein synthesis machinery.

These results establish a new paradigm in antiviral strategy—targeting host autophagy pathways, specifically BIRC3-mediated signaling, to suppress viral replication. The high selectivity index and the use of a clinically approved molecule underscore the translational potential of this approach.

Comparison with Existing Internal Articles

While the reference study focuses on host-directed antiviral therapy, recent advances in epigenetic modulation—particularly through small molecule DNA methyltransferase inhibitors (DNMTis) like RG108—offer conceptual parallels. For instance, "Unlocking Translational Potential: RG108 DNA Methyltransferase Inhibitor" discusses the non-covalent, non-cytotoxic modulation of gene expression for disease intervention, a strategy analogous to the host-centric mechanism of 6-TG in EV71. Further, studies using RG108 illustrate the power of manipulating cellular pathways—such as epigenetic gene regulation—for developmental and disease models. Although the mechanistic targets differ (BIRC3/autophagy versus DNMT/epigenetic modifications), both approaches exemplify how small molecule modulators can shift cellular states to counteract pathology, whether viral or oncogenic.

Limitations and Transferability

The findings by You et al. are robust in an in vitro context, yet several caveats remain:

• The study is limited to human intestinal epithelial cells; in vivo efficacy and safety require further validation.
• EV71 genotype diversity and the complexity of autophagic regulation in vivo may affect the generalizability of results.
• Potential off-target effects of 6-TG, given its known roles in DNA synthesis and immune modulation, warrant careful assessment in translational studies.

Such limitations highlight the importance of complementary tools in dissecting host-pathogen interactions and underscore the need for further research before clinical translation.

Protocol Parameters

• Cell type: HT-29 human colon adenocarcinoma cells were used for modeling EV71 infection.
• 6-TG treatment: Dose-response assays indicate an IC₅₀ of 0.93 μM for antiviral activity; cytotoxicity was negligible up to 2000 μM in HT-29 cells.
• Viral load readouts: Quantification of EV71 mRNA (qPCR), VP1 protein (immunoblotting), and progeny infectious units (plaque assay) following compound treatment.
• Host protein assessment: BIRC3 and autophagy markers were measured to elucidate mechanistic effects.

For studies of epigenetic gene regulation, researchers often employ DNA methyltransferase inhibitors such as RG108 at 50 μM for 48 hours in HL-60 cells, as described in product documentation.

Research Support Resources

To enable further exploration of host-pathogen and epigenetic regulatory mechanisms, reagents like RG108 (SKU A1913) are available for controlled DNA methyltransferase inhibition and gene reactivation studies. RG108 is a well-characterized, non-nucleosidic DNA methyltransferase inhibitor suitable for in vitro workflows in cancer research and epigenetic gene regulation modulation. For experimental details and handling, refer to the manufacturer’s guidance. Researchers can integrate such tools alongside host-targeted antiviral approaches to dissect the interplay between epigenetic modifications and cellular defense pathways. (APExBIO)